FDA orders tissue-recovery firm to stop manufacturing
This article was originally published in RAJ Devices
The US Food and Drug Administration (FDA) has ordered a US human tissue-recovery firm based in Raleigh, North Carolina and its owner, to stop all manufacturing operations after inspections found serious deficiencies in its manufacturing practices. Donor Referral Services and its owner, Philip Guyett, were also ordered to retain the human cells, tissues and cellular and tissue-based products (HCT/Ps) recovered on or after 25 May 2005 and which were still in the company's possession.
You may also be interested in...
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.